Form 4: Macrogenics VP, Controller & Treasurer Beth Ann Smith Reports Stock Transactions

Beth Ann Smith, VP, Controller & Treasurer of Macrogenics Inc, reports acquisition and disposal of common stock and derivative securities.

Summary

• On February 8, 2025, Beth Ann Smith, VP, Controller & Treasurer of Macrogenics Inc, reported transactions involving the company's stock.
• Smith acquired 1,583 shares of common stock through the vesting of restricted stock units.
• She also disposed of 612 shares to cover tax obligations at a price of $2.6 per share.
• Following these transactions, Smith directly owns 8,860 shares of common stock.
• Additionally, Smith acquired 47,050 employee stock options and 7,850 restricted stock units on February 7, 2025.
• The restricted stock units vest over three years, with 33% vesting annually.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing of insider transactions. The acquisition of shares through vesting is mildly positive, while the disposal for tax obligations is neutral.

Positives

• The vesting of restricted stock units and granting of employee stock options and RSUs could be seen as a positive sign of confidence in the company's future performance.

Negatives

• The disposal of shares to cover tax obligations, while common, could be interpreted as a slight negative, although it's a standard practice.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedule of the restricted stock units and the exercisability of the stock options suggest a continued involvement and alignment of the reporting person with the company's long-term performance.

Industry Context

This Form 4 filing is a routine disclosure related to insider transactions. It's common for executives to receive stock options and restricted stock units as part of their compensation packages, and their subsequent transactions are closely monitored by investors for insights into their confidence in the company.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation practices in the biotechnology industry, used to incentivize and retain key personnel.
• Vesting schedules, such as the one described (33% annually), are typical for these types of equity grants.
• The disposal of shares to cover tax obligations is also a common occurrence among executives who receive equity compensation.

Stakeholder Impact

• The transactions may have a minor impact on shareholders, as they provide insight into management's actions regarding their holdings in the company.
• Employees may be impacted by the granting of stock options and RSUs, as it affects their compensation and potential ownership in the company.

Key Dates

Keywords

Macrogenics, MGNX, Form 4, insider trading, stock options, restricted stock units, common stock, Beth Ann Smith, vesting